MicroPort NeuroTech Limited (2172.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Sector
Healthcare
Industry
Medical - Devices
Employees
527
First IPO Date
July 15, 2022
| Name | Title | Pay | Year Born |
| Zhiyong Xie | Chief Executive Officer, Executive Director & Chairman of MicroPort NeuroTech | 1.24M | 1976 |
| Yiqun Wang | Senior Vice President & Executive Director | 1.82M | 1965 |
| Siu Lam Yeung | Company Secretary | 0 | N/A |
| Zaoli Wu | Manager of Human Resources & Administration | 0 | 1983 |
| Lei Duan | Chief Marketing Officer and SVP of Sales & Promotion of Neurovascular Disease Treatment Solutions | 0 | 1982 |
| Zhuoping Hou | Senior Director of Finance | 0 | 1978 |
| Wangcai Liao | Chief Technology Officer | 0 | 1964 |
Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.